Y-mAbs Therapeutics Reports Q2 2025 Earnings Amid Merger Talks and Declining Revenue Trends

Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) has released its quarterly report for Q2 2025, marking significant developments amidst an ongoing merger agreement.

Key Financial Highlights:

• Net Product Revenue: $19.0 million for Q2 2025, down from $22.8 million in Q2 2024 (-17%).
• Total Revenues: $19.5 million for Q2 2025, compared to $22.8 million in Q2 2024 (-14%).
• Gross Profit: $16.9 million in Q2 2025, down from $19.8 million in Q2 2024.
• Loss from Operations: $5.6 million in Q2 2025 vs $9.8 million in Q2 2024 (43% improvement).
• Net Loss: $3.2 million for Q2 2025, improved from $9.2 million in Q2 2024 (65% decrease).
• Net Cash Used in Operating Activities: $5.3 million for the six months ended June 30, 2025.
• Cash and Cash Equivalents: $62.3 million as of June 30, 2025.

Operating Costs:

• Research and Development Expenses: $11.1 million in Q2 2025, down from $12.3 million (10% decrease).
• Selling, General, and Administrative Expenses: $11.3 million in Q2 2025, compared to $17.2 million (34% decrease).
• Stock-Based Compensation: Totaled $6.2 million for the first half of 2025.

Company Developments:

• Agreed to a Merger Agreement with Perseus BidCo US, Inc., with a cash tender offer of $8.60 per share anticipated to begin by August 19, 2025.
• Continued focus on expanding the commercialization of DANYELZA, achieving over $39 million in product revenue in the first half of 2025.
• Severe losses since inception, now totaling around $496 million.

Legal Matters:

• Ongoing litigation related to shareholder lawsuits, including settlements affecting operational cash flows; total settlement costs reached approximately $19.7 million.

Positive Aspects:

• Improvement in net loss compared to previous quarters.
• Significant cash reserves of $62.3 million may support future operations and product development.

Negative Aspects:

• Declining revenue trends primarily from the US market due to competition and clinical trial enrollments.
• Accumulated deficits continue to grow as the company invests heavily in research and development expenses.

The upcoming merger and ongoing legal challenges present considerable uncertainty for Y-mAbs Therapeutics, while revenue generation from DANYELZA remains critical to its prospects.